M 23

Drug Profile

M 23

Alternative Names: rscu-PA-40kDa/Hir

Latest Information Update: 31 May 2001

Price : $50

At a glance

  • Originator Grunenthal
  • Class Thrombolytics
  • Mechanism of Action Plasminogen activator stimulants; Platelet aggregation inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 31 May 2001 Discontinued-Preclinical for Thrombosis in Germany (Unknown route)
  • 14 Mar 2000 No-Development-Reported for Thrombosis in Germany (Unknown route)
  • 23 May 1997 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top